Compare American International Group Inc (AIG) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Amgen, Inc. — how do they compare? American International Group Inc trades at $77.14 (market cap $40.42B), while Amgen, Inc. trades at $412.77 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 5.5× American International Group Inc's market cap, and American International Group Inc pays the higher dividend (2.59%). Which is the better fit depends on your goals.
| AIG | AMGN | |
|---|---|---|
Market Cap | $40.42B | $224.14B |
Sector | Financials | Health |
52-Week High | $86.59 | $417.20 |
52-Week Low | $71.89 | $271.18 |
Enterprise Value | $48.06B | $267.45B |
Dividend Yield | 2.59% | 2.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
